Nanjing Pharmaceutical Group Company Limited (SHA:600713)

SHA:600713 Revenue

Nanjing Pharmaceutical Group Company had revenue of 13.84B CNY in the quarter ending March 31, 2026, a decrease of -2.83%. This brings the company's revenue in the last twelve months to 54.56B, up 1.06% year-over-year. In the year 2025, Nanjing Pharmaceutical Group Company had annual revenue of 54.96B with 2.36% growth.

• Revenue (ttm): 54.56B
• Revenue Growth: +1.06%
• P/S Ratio: 0.12
• Revenue / Employee: 11.62M
• Employees: 4,697
• Market Cap: 6.45B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	54.96B	1.27B	2.36%
Dec 31, 2024	53.70B	106.51M	0.20%
Dec 31, 2023	53.59B	3.37B	6.71%
Dec 31, 2022	50.22B	5.10B	11.30%
Dec 31, 2021	45.12B	5.31B	13.33%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 28, 2026

Data Sources Report a data error